sglt2 inhibitors vs glp-1 and Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application GLP-1 Receptor Agonist Therapy With

In addition to their significant A1C-lowering effects, the landmark clinical trials for these respective agents found substantial appetite suppression, less feeling of "reward" after eating, and subsequent weight loss

GI side effects may further compromise nutrient absorption and exacerbate preceding or new risk of nutrient insufficiency

Once prescribed by our medical providers, your prescription is sent to our partner GLP-1 compounding pharmacy (or in some cases, another pharmacy of your choosing)

Key hormones released by EECs include GLP-1, GIP, cholecystokinin (CCK), ghrelin, and peptide YY (PYY)

This is not a prescription medication but should be discussed if you take other medications

As a result, the safety and tolerability profile of retatrutide aligns with other incretin-based therapies (hormones produced by the gut that help regulate blood sugar levels)